12 October 2015 - The Biosafety Council issues a positive advice (with conditions) for this trial
Trial reference:
A Phase 1b/3, Multicenter, Open-label Trial of Talimogene Laherparepvec in Combination With Pembrolizumab (MK-3475) for Treatment of Unresected, Stage IIIB to IVM1c Melanoma